Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L B Grochow

Showing results (1-10 of 85) with videos related to

Pageof 9
Sort By:
Seminars in Oncology|August 1, 1993
Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimensL B Grochow
The Surgical Clinics of North America|October 1, 1995
Adjuvant therapy with chemotherapy and radiation therapy in the management of carcinoma of the pancreatic headR A Abrams, L B Grochow
Drugs|June 14, 2000
Clinical potential of matrix metalloprotease inhibitors in cancer therapyE I Heath, L B Grochow
Clinics in Geriatric Medicine|February 1, 1997
Pharmacology of cancer chemotherapy in the older personS D Baker, L B Grochow
Lancet (London, England)|March 28, 1987
Unusual opioid withdrawal syndrome. A case-reportK M Kumor, L B Grochow, F Hausheer
Blood|April 15, 1990
Busulfan disposition in childrenL B Grochow, W Krivit, C B Whitley, et al.
Journal of Chromatography|March 18, 1988
Determination of busulfan in human plasma by gas chromatography with electron-capture detectionT L Chen, L B Grochow, L A Hurowitz, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1989
A phase I trial of trimetrexate glucuronate (NSC 352122) given every 3 weeks: clinical pharmacology and pharmacodynamicsL B Grochow, D A Noe, D S Ettinger, et al.
Anti-Cancer Drugs|June 1, 1996
A phase II trial of topotecan in patients with previously untreated pancreatic cancerS O'Reilly, R C Donehower, E K Rowinsky, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|February 1, 2002
Metabolism and urinary excretion of a new quinoline anticancer drug, TAS-103, in humansR Azuma, M Saeki, Y Yamamoto, et al.
Pageof 9

Showing results (1-10 of 85) with videos related to

Sort By:
Pageof 9
Seminars in Oncology|August 1, 1993
Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimensL B Grochow
The Surgical Clinics of North America|October 1, 1995
Adjuvant therapy with chemotherapy and radiation therapy in the management of carcinoma of the pancreatic headR A Abrams, L B Grochow
Drugs|June 14, 2000
Clinical potential of matrix metalloprotease inhibitors in cancer therapyE I Heath, L B Grochow
Clinics in Geriatric Medicine|February 1, 1997
Pharmacology of cancer chemotherapy in the older personS D Baker, L B Grochow
Lancet (London, England)|March 28, 1987
Unusual opioid withdrawal syndrome. A case-reportK M Kumor, L B Grochow, F Hausheer
Blood|April 15, 1990
Busulfan disposition in childrenL B Grochow, W Krivit, C B Whitley, et al.
Journal of Chromatography|March 18, 1988
Determination of busulfan in human plasma by gas chromatography with electron-capture detectionT L Chen, L B Grochow, L A Hurowitz, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1989
A phase I trial of trimetrexate glucuronate (NSC 352122) given every 3 weeks: clinical pharmacology and pharmacodynamicsL B Grochow, D A Noe, D S Ettinger, et al.
Anti-Cancer Drugs|June 1, 1996
A phase II trial of topotecan in patients with previously untreated pancreatic cancerS O'Reilly, R C Donehower, E K Rowinsky, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|February 1, 2002
Metabolism and urinary excretion of a new quinoline anticancer drug, TAS-103, in humansR Azuma, M Saeki, Y Yamamoto, et al.
Pageof 9